Eovist® & Nephrogenic Systemic Fibrosis

Tweet

Eovist® contrast agents with gadolinium have recently been linked to Nephrogenic Systemic Fibrosis (NSF), also known as Nephrogenic Fibrosing Dermopathy (NFD), a horrible and potentially fatal disease.

Free Eovist NSF Case Evaluation: If you or a loved one has been injured by Eovist contrast dye, you should contact our law firm immediately. You may be entitled to compensation by filing a lawsuit and we can help.

What is Eovist?

Eovist is the trade name for gadoxetate disodium, a drug used as a paramagnetic contrast agent during MRI scans marketed by Bayer. MRI stands for Magnetic Resonance Imaging, which is a commonly used medical diagnosis technique in radiology. It uses powerful magnets to differentiate between soft tissues, skeletal and the nervous system. Eovist is given to enhance the MRI image, showing tumors and lesions clearly.

Nephrogenic Systemic Fibrosis (NSF) & Eovist Contrast Dye

NSF is a disease characterized by the hardening of skin and other body tissues as a result of gadolinium contrast agents – such as Eovist – breaking down in the human body. Typically, the skin first begins hardening around the ankles and/or wrists. The disease is progressive. The skin hardening usually then spreads up the legs and arms, and to the torso. Tissue in joints, muscles and internal organs may harden as well, making the disease potentially fatal.

Many health care providers are not familiar with NSF because it is a relatively new disease. The first cases of NSF were identified in 1997, and the first published report of NSF cases appeared in 2000.  The link between NSF and gadolinium was only revealed in 2006. At present, there is no known cure for NSF, and treatments are still in the experimental stage.

Do I have an Eovist NSF Lawsuit?

The Product Liability Litigation Group at our law firm is an experienced team of trial lawyers that focus exclusively on the representation of plaintiffs in Eovist NSF lawsuits. We are handling individual litigation nationwide and currently accepting new cases in all 50 states.